GlobeNewswire Inc | Mar 10, 2021 08:00AM EST

March 10, 2021

NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP) platform technology, today announced that management will participate in the 33rd Annual Roth Conference, which will be held on March 15-17, 2021. Management will host virtual one-on-one meetings during the conference.

Institutional investors interested in a one-on-one meeting with Eyenovia management should contact their ROTH institutional sales representative.

AboutEyenovia, Inc.

Eyenovia, Inc.(NASDAQ: EYEN) is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP) platform technology. Eyenoviais currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, visitwww.eyenovia.com.

Eyenovia Contact: Eyenovia, Inc. John Gandolfo Chief Financial Officerjgandolfo@eyenovia.com

Eyenovia Investor Contact: Eric Ribner LifeSci Advisors, LLCeric@lifesciadvisors.com (646) 751-4363

Eyenovia Media Contact: Diana Soltesz Pazanga Health Communicationsdsoltesz@pazangahealth.com (818) 618-5634